BofA analyst Geoff Meacham initiated coverage of Avidity Biosciences with a Buy rating and $40 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences files to sell 24.26M shares of common stock for holders
- Avidity Biosciences initiated with an Overweight at Cantor Fitzgerald
- Dyne Therapeutics price target raised to $37 from $33 at Guggenheim
- Avidity Biosciences price target raised to $33 from $23 at Chardan
- Avidity Biosciences Reveals Promising Trial Results and Phase 3 Plans